Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Dec:208:14-17.
doi: 10.1016/j.thromres.2021.10.008. Epub 2021 Oct 13.

Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report

Bernadette Corica  1 , Antonella Cacciani  2 , Roberto Cangemi  1 , Marcella Visentini  1 , Fabrizio Recchia  1 , Rosalba Grillo  1 , Marco Vano  1 , Nicolò Sperduti  1 , Alessandro Cincione  1 , Giovanni Buoninfante  1 , Fabio Pulcinelli  3 , Antonio Chistolini  1 , Adriano De Santis  1 , Davide Flego  1 , Giulio Francesco Romiti  1 , Stefania Basili  4 , Lucia Stefanini  1
Affiliations
Case Reports

Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report

Bernadette Corica et al. Thromb Res. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SB received a research grant from MSD, outside the scope of this study.

Figures

Fig. 1
Fig. 1
Platelets levels and clinical course during hospital stay and follow-up. Legend: CT: Computed tomography; IVIG: Intravenous Immunoglobulin; US: Ultrasound.
Fig. 2
Fig. 2
Platelet surface receptor expression during hospital stay and follow-up. Panel A: glycoprotein GPVI; Panel B: integrin CD41a (total integrin αIIb); Panel C: PAC1 (active integrin αIIbβ3); Panel D: active/total integrin ratio. Legend: CI = Confidence Intervals; GPVI = Glycoprotein VI; MFI = Median Fluorescence Intensity, PLT = Platelets, r.i.: reference intervals (compared to the levels found among 34 healthy controls).
See this image and copyright information in PMC

References

    1. Folegatti P.M., Ewer K.J., Aley P.K., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383(27):2603–2615. Available from: - PMC - PubMed
    1. Greinacher A., Thiele T., Warkentin T.E., et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 2021;384(22):2092–2101. - PMC - PubMed
    1. Umbrello M., Brena N., Vercelli R., et al. Successful treatment of acute spleno-Porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report. J. Crit. Care. 2021;65:72–75. - PMC - PubMed
    1. Lavin M., Elder P.T., O’Keeffe D., et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations. Br. J. Haematol. 2021;195(1):76–84. - PMC - PubMed

Substances